ZANTAC SWITCH TO NONPRESCRIPTION STATUS IN U.K. PROPOSED
This article was originally published in The Tan Sheet
Executive Summary
ZANTAC SWITCH TO NONPRESCRIPTION STATUS IN U.K. PROPOSED by that country's Medicines Control Agency in a July 1 "consultation letter" offered to interested parties for comment. Under an agreement announced in August 1993, the nonprescription version of Glaxo's Zantac (ranitidine) will be marketed by Warner Wellcome in the U.K. The product will be indicated for short-term symptomatic relief of heartburn, dyspepsia and hyperacidity as an OTC.